In 2004, the WHO introduced rapid diagnostic tests (RDTs) for the biological diagnosis of malaria. However, the policy of the National Malaria Control Program (PNLP) reserves RDTs for peripheral facilities and thick blood tests for hospitals with adequate technical facilities, including clinical biology laboratories. Aim: The aim of our study was to assess the epidemiological and clinical aspects of severe RDT-positive malaria in the paediatric department of the UHGT. Patients and Methods: This was a prospective, cross-sectional, descriptive study conducted over a six-month period (1 July to 31 December 2019) in children aged 1 month to 15 years hospitalised in the paediatric department for severe RDT-positive malaria. Results: The hospital frequency was 23.7%. Children aged 01 to 59 months were the most affected (53.7%). Males were the most common (58%). Fever was the most frequent reason for consultation (85.9%). Cerebral malaria was the most common clinical phenotype (66.1%). RDTs and thick blood tests wer positive in 69% of cases. RDT alone was positive in 31%. Artesunate injection was the aetiological treatment used in our patients (100%), with a case fatality rate of 24.4% and an average hospital stay of 5 days. Conclusion: The use of the malaria RDT has enabled rapid diagnosis and management of severe malaria cases at the CHU-GT.